Anti-MEGF9 monoclonal antibody

Pre-made anti-MEGF9 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MEGF9/MEGF9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1166-Ab-1/ GM-Tg-hg-IP1166-Ab-2Anti-Human MEGF9 monoclonal antibodyHuman
GM-Tg-rg-IP1166-Ab-1/ GM-Tg-rg-IP1166-Ab-2Anti-Rat MEGF9 monoclonal antibodyRat
GM-Tg-mg-IP1166-Ab-1/ GM-Tg-mg-IP1166-Ab-2Anti-Mouse MEGF9 monoclonal antibodyMouse
GM-Tg-cynog-IP1166-Ab-1/ GM-Tg-cynog-IP1166-Ab-2Anti-Cynomolgus/ Rhesus macaque MEGF9 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1166-Ab-1/ GM-Tg-felg-IP1166-Ab-2Anti-Feline MEGF9 monoclonal antibodyFeline
GM-Tg-cang-IP1166-Ab-1/ GM-Tg-cang-IP1166-Ab-2Anti-Canine MEGF9 monoclonal antibodyCanine
GM-Tg-bovg-IP1166-Ab-1/ GM-Tg-bovg-IP1166-Ab-2Anti-Bovine MEGF9 monoclonal antibodyBovine
GM-Tg-equg-IP1166-Ab-1/ GM-Tg-equg-IP1166-Ab-2Anti-Equine MEGF9 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1166-Ab-1/ GM-Tg-hg-IP1166-Ab-2; GM-Tg-rg-IP1166-Ab-1/ GM-Tg-rg-IP1166-Ab-2;
GM-Tg-mg-IP1166-Ab-1/ GM-Tg-mg-IP1166-Ab-2; GM-Tg-cynog-IP1166-Ab-1/ GM-Tg-cynog-IP1166-Ab-2;
GM-Tg-felg-IP1166-Ab-1/ GM-Tg-felg-IP1166-Ab-2; GM-Tg-cang-IP1166-Ab-1/ GM-Tg-cang-IP1166-Ab-2;
GM-Tg-bovg-IP1166-Ab-1/ GM-Tg-bovg-IP1166-Ab-2; GM-Tg-equg-IP1166-Ab-1/ GM-Tg-equg-IP1166-Ab-2
Products NameAnti-MEGF9 monoclonal antibody
Formatmab
Target NameMEGF9
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MEGF9 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1166-Ag-1Recombinant multi-species MEGF9/ EGFL5 protein


    Target information

    Target IDGM-IP1166
    Target NameMEGF9
    Gene ID1955,230316,313270,704605,481698,100151765,533820,100146310
    Gene Symbol and Synonyms4933405H16Rik,9630025C07,EGFL5,MEGF9,mKIAA0818
    Uniprot AccessionQ9H1U4
    Uniprot Entry NameMEGF9_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000106780
    Target ClassificationN/A

    The target: MEGF9, gene name: MEGF9, also named as EGFL5. Predicted to be involved in several processes, including animal organ morphogenesis; cell migration; and substrate adhesion-dependent cell spreading. Predicted to be integral component of membrane. Predicted to be active in basement membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.